Small Molecules
15 February 2013
Medical Imaging Drugs Advisory Committee Recommends Approval of Guerbet NDA for Dotarem (gadoterate meglumine)15 February 2013
Algeta ASA : Further sub-analyses of ALSYMPCA phase III study presented at 2013 Genitourinary Cancers Symposium15 February 2013
Promising Preclinical and Phase I Data of a New Generation Androgen Receptor (AR) Inhibitor, ODM- 201, Presented at ASCO GU 2013 Symposium15 February 2013
Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium15 February 2013
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease14 February 2013
Scioderm’s Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA14 February 2013
Auris Medical completes enrolment in TACTT1 study with AM-101 for the treatment of acute peripheral tinnitus13 February 2013
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration13 February 2013
Radium-223 Dichloride Granted Priority Review by U.S. FDA12 February 2013
Phase 3 Trial of ZIOPHARM’S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events11 February 2013
Catabasis Announces Positive Phase 1 Data for CAT-1004 Validating the SMART Linker Technology Platform11 February 2013
Celgene Provides REVLIMID Regulatory Update11 February 2013
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-1889 February 2013
POZEN Presents Positive PA32540 Phase 3 Data at the 2013 International Stroke Conference7 February 2013
Omeros Announces Toxicology Study Data from MASP-2 Inhibitor7 February 2013
Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-7866 February 2013
Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics5 February 2013
Xarelto to be Studied with Factor Xa Inhibitor Antidote5 February 2013
Verastem Initiates Phase 1/1b Clinical Trial of VS-6063 Plus Paclitaxel for Patients with Ovarian CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports